Price Cuts at Novo Nordisk
You may have seen headlines lately that pharmaceutical giant Novo Nordisk ($NVO) will enact significant price cuts for its blockbuster weight loss drugs Ozempic, Wegovy, and Rybelsus starting in 2027. Novo Nordisk is cutting prices because it’s facing stiff competition from Eli Lilly &Co. ($LLY) and pressure from government regulators to make the popular drugs more affordable. The cuts will lower the price for a one-month supply to $675, which translates into reductions of from 35 to 50 percent depending on the exact drug. For financial analysts, an important question emerges: Just how much money does Novo Nordisk make from these drugs, anyway? As always, Calcbench can help. Novo Nordisk is based in Denmark, and as a foreign issuer its annual report is known as a Form 20-F. In that report, however, the company does report the sales of individual drugs just like U.S. pharmaceutical companies do. (We have a pharmaceutical sales template available for Calcbench premium subscr...